KLRC1 and neoplasm: We found that ∼20% of B16F10‐GP tumor recipients who received anti‐NKG2A‐blocking mAb or anti‐PD‐L1‐blocking mAb were in complete remission, while the recipients of control group were not able to survive at day 25 posttumor engraftment (Figure 4B).